Loading company…
VerImmune develops a cancer therapy designed to redirect existing immune responses toward tumor cells.
VerImmune's ViP platform uses virus-inspired particles to harness immune memory against pathogens and childhood vaccines for cancer treatment. Founded in 2019, it is based in Washington, US, and raised USD 500,000 in venture funding from TEDCO in November 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in